This webinar focuses on effective strategies for engaging justice-involved populations and ways to support individuals transitioning to communities. The speakers shared case studies to illustrate the ways that providers have managed transitions of care and supported people. This session is approved by the American Academy of Family Physicians for up to 1 AMA Level 1 CME credit.
The toolkit contains a variety of information and resources including a step by step guide about:
education about tobacco use
skills for engaging people in tobacco cessation discussions
efficient methods for assessing readiness to quit
information and research on treatments
The research presented by these three groups seeks to prioritize desired treatment outcomes as defined by diverse people with lived experience. From this information, the researchers crafted recommendations that could help policymakers, providers and researchers develop, implement, reimburse and evaluate more engaging and perhaps effective substance use services.
The goal of the ICTA program is to improve care and Medicaid beneficiary outcomes within three practice transformation core competencies:
Delivering person-centered care across the care continuum
Using population health analytics to address complex medical, behavioral health, and social needs; and
Engaging leadership to support value-based care.
This document provides more detail, including sub-elements for each core competency.
People with substance use disorders are at particular risk for overdoses and developing one or more primary conditions or chronic diseases. During this webinar, presenters will discuss harm reduction as a public health approach that aims to reduce harms related to substance use. Presenters will discuss strategies, policies, programs, and practices that aim to minimize negative health, social and legal impacts associated with drug use, drug policies, and drug laws.
This document contains information about assessing the need for treatment; initiating MAT; monitoring patient progress and adjusting treatment plan; deciding whether and when to end MAT.
The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item screening tool developed by the WHO to assess alcohol consumption, drinking behaviors, and alcohol-related problems.
Screening and brief intervention provides an opportunity for clinicians to intervene early and potentially enhance medical care by increasing awareness of the likely impact of substance use on a patient’s overall health.
This document consists of common questions and concerns about Medication Assisted Treatment for Ambivalent patients. This document can be used as a starting point to have conversations with your patients. In the end, the patient will be able to make an informed decision that’s in line with their values and hopes for recovery.
This question and answer document answers common questions and concerns that family members have about Medication Assisted Treatment (MAT). The purpose of this document is to assist providers in educating family members.
Patients can use this Early Recovery Handout to determine behaviors when cravings or urges arise or behaviors have changed. The document provides strategy to mitigate any behavioral outliers while keeping the patient on track from day to day.
This article reviews research findings in the following 7 areas: location of buprenorphine induction, combining buprenorphine with a benzodiazepine, relapse during buprenorphine treatment, requirements for counseling, uses of drug testing, use of other substances during buprenorphine treatment, and duration of buprenorphine treatment.
The Medication-Assisted Treatment Of Opioid Use Disorder pocket guide to provide guidance on how to assess the need for treatment, referring to higher levels of care if necessary and the approved frequency and route of administration for treatment of Opioid Use Disorder. In addition, a tool has been provided to determine clinical opiate withdrawal.
The Substance Abuse and Mental Health Services Administration provides guidance for substance use disorder treatment services during the COVID-19 pandemic. The document specifies when a medical emergency exists, 42 C.F.R Part 2 does not apply and any disclosure of medical information is temporarily exempt for purposes of medical treatment.
The frequently asked questions document discusses how providers can provide Opioid Treatment to existing and new patients, and dispense medications via Telehealth while still meeting the 42 C.F.R. 8.11 requirements.
During the webinar, the presenter will focus on ways to address health equity issues and key considerations for providing linguistically effective services. The presenter will discuss best practices and models to support patients in these challenging times.
Understanding the brain chemistry associated with opioid use disorder treatment is essential: Medications for Addiction Treatment (MAT) restores depleted dopamine in the brain so people impacted by OUD can regain functioning. Recognizing this, therapy and support services for OUD are most effective when provided in accordance with a person's healing process and readiness to engage in treatment.
The American Society of Addiction Medicine (ASAM) has established specific criteria for patient assessments and level of care determinations pertaining to substance use disorder (SUD) – providing the underpinnings for effective treatment and recovery from addiction. This webinar will provide attendees with practical tools and tips for implementation of Screening Brief Intervention and Treatment (SBIRT) including assessments, workflows, and reimbursement.
This webinar will describe how stigma impacts perceptions and resultant SUD care for patients and providers alike. Presenters will also share key concepts and case studies to illustrate ways to address stigma and tools that can be incorporated into their clinical practice.
This module offers a 25-minute video of the neuroscience of addiction as a chronic brain disease presented by HMA’s Corey Waller, MD, MS, FACEP, DFASAM, with emphasis on Opioid Use Disorder (OUD).
"This lecture was developed for audiences of all backgrounds to absorb. From patients to nonspecialist docs. The intent was to move people past the preconceived notion that addiction is a moral failing or choice, to the reality that it is a chronic brain disease that creates maladaptive connections in large swaths of the brain. Over the hundreds of lectures, I have given in my career, I have come to realize that running through 30+ articles in a 70 slide PPT does not move people emotionally. But a good story will. The lecture has coalesced into a story form that is much more compelling than digging through the dense science of voxel dysmorphology, BOLD fMRI technology, and all of the structures postulated to drive craving. If I need a custody officer to "get it" or an administrator to understand the concept, I cannot give them the same lecture I would give a psychiatrist, addiction psychologist, addiction doc, or a neurologist."
Deeper dive on the operational practicalities of delivering MAT and other SUD treatment to clients through telehealth and other remote means; risk and management of relapse and overdose; current expectations regarding privacy rules, documentation, and new regulations from the DEA.
The webinar presents policy and reimbursement implications for changes regarding Medicare and Medicaid and the impacts on key provider decisions concerning selecting, implementing, and building a business case for new telehealth services to support patients in these challenging times.
This webinar focused on the appropriate screening and assessments for substance use disorders, including the difference between screening and assessment, brief interventions for substance-related issues, and medications for opioid use disorder.
This webinar presented the Stepped Care Approach, including validated screening tools, strategies and resources for patients with mild, moderate or urgent behavioral health care needs.
